- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05396833
Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor M1774 in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: US Medical Information
- Phone Number: 888-275-7376
- Email: eMediUSA@emdserono.com
Study Contact Backup
- Name: Communication Center
- Phone Number: +49 6151 72 5200
- Email: service@emdgroup.com
Study Locations
-
-
-
Toronto, Canada, M5G 2C1
- Recruiting
- Princess Margaret Cancer Centre
-
-
-
-
-
Barcelona, Spain, 08023
- Recruiting
- Hospital QuironSalud Barcelona - Next Oncology
-
Madrid, Spain, 28223
- Recruiting
- Hospital Universitario Quironsalud Madrid - NEXT Oncology
-
-
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas M. D. Anderson Cancer Center - Partner
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Part A1, A1.1, A2, A3, and A2/3: Participants with metastatic or locally advanced unresectable solid tumors refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator, which may convey clinical benefit, or who cannot tolerate standard of care treatment
- Part A1.1: Triple negative breast cancer, epithelial ovarian cancer, castrate resistant prostate cancer, urothelial cancer, endometrial cancer, and colorectal cancer independent of mutation status.
- Part A2: Patients with advanced prostate cancer whose tumor carries a genetic loss of function (LoF) mutation(s) in the gene ataxia telangiectasia mutated (ATM).
No more than 3 prior lines of therapy for castrate resistant disease. Prior therapy must have included a taxane and a novel antiandrogen (example [e.g.] enzalutamide).
- Part A3: Patients with advanced endometrial cancer whose tumor carries a genetic LoF mutation(s) in the gene AT-rich interaction domain 1A (ARID1A).
Prior therapy must have included a platinum agent. Prior therapy must also have included a checkpoint inhibitor if the patient has mismatch repair (MMR)-deficient endometrial cancer. - Note for Parts A2/A3: Patients with ATM LoF mutated prostate cancer and ARID1A LoF mutated endometrial cancer should be prioritized to the respective expansion arms instead of being enrolled in Part A1.1. The presence of ATM and ARID1A LoF mutations will be determined according to local data, generated by an assay with appropriate regulatory status, in either tumor or liquid biopsy. The Sponsor will confirm that mutations certified by local data fulfil this definition.
- Participants with eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with estimated life expectancy of at least 3 months
- Adequate hematological, hepatic, and renal function as defined in the protocol
- Other protocol defined inclusion criteria could apply
Exclusion Criteria:
- Participants with any condition, including any uncontrolled disease state other than with metastatic or locally advanced unresectable solid tumors, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
- Participants with a known additional malignancy that is progressing and/or requires active treatment
- Participants with carcinomatous meningitis are excluded regardless of clinical stability
- Participants with serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease, and/or other situations that may preclude adequate absorption of oral medications
- Participants with organ transplantation, including allogeneic stem cell transplant
- Other protocol defined exclusion criteria could apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A1: M1774 and M4076
|
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
M4076 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
|
Experimental: Part B1: M1774 and Avelumab
|
Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
|
Experimental: Part A1.1: M1774 and M4076
Assessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076
|
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
M4076 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
|
Experimental: Part A2: M1774 and M4076
ATM in prostate cancer (Part A2)
|
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
M4076 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
|
Experimental: Part A3: M1774 and M4076
ARID1A in endometrial cancer (Part A3
|
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
M4076 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
|
Experimental: Part A2/A3: M1774 and M4076
Tablet formulation (TF1, test) compared to a capsule formulation (reference)
|
M1774 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
M4076 will be administered orally once daily over a defined period of time in Part A1, A1.1, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Time Frame: Day 1 up to Day 28
|
Day 1 up to Day 28
|
|
Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Time Frame: Day 1 up to Day 28
|
Day 1 up to Day 28
|
|
Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEs
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
|
Part B1: Number of Participants with AEs and Treatment-Related AEs
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
|
Part A1: Change From Baseline in Pharmacodynamic (PD) Biomarker
Time Frame: Pre-dose up to approximately 1 month
|
The PD biomarker of histone variant will be measured by flow cytometry.
|
Pre-dose up to approximately 1 month
|
Part B1: Change From Baseline in PD Biomarker
Time Frame: Pre-dose up to approximately 1 month
|
The PD biomarker of histone variant will be measured by flow cytometry.
|
Pre-dose up to approximately 1 month
|
Part A1.1: PK Plasma Concentration of M4076 Under Fed and Fasted Conditions
Time Frame: Day -1 up to Period 1 Day 1
|
Day -1 up to Period 1 Day 1
|
|
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of M1774 Test Treatment Compared to M1774 Reference Treatment
Time Frame: Day -4 up to Period 1 Day 1
|
Day -4 up to Period 1 Day 1
|
|
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of M1774 Test Treatment Compared to M1774 Reference Treatment
Time Frame: Day -4 up to Period 1 Day 1
|
Day -4 up to Period 1 Day 1
|
|
Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of M1774 Test Treatment Compared to M1774 Reference Treatment
Time Frame: Day -4 up to Period 1 Day 1
|
Day -4 up to Period 1 Day 1
|
|
Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by Investigator
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
|
Part A2/A3: Number of Participants With AEs and Treatment-Related AEs
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part B1: Pharmacokinetic (PK) Plasma Concentration of M1774
Time Frame: Pre-dose up to approximately 6 months
|
Pre-dose up to approximately 6 months
|
Part A1 and B1: Number of Participants with Clinically Significant Abnormalities in Digital Electrocardiogram (ECG) Measures
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
Part A1 and B1: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
Part A1: Pharmacokinetic (PK) Plasma Concentration of M1774 and M4076
Time Frame: Pre-dose up to approximately 6 months
|
Pre-dose up to approximately 6 months
|
Part B1: Pharmacokinetic (PK) Serum Concentration of Avelumab
Time Frame: Pre-dose up to approximately 18 months
|
Pre-dose up to approximately 18 months
|
Part B1: Number of Participants with Any Positive Anti-Drug Antibody (ADA) of Avelumab
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
Part A1.1: Number of Participants With AEs and Treatment-Related AEs
Time Frame: Baseline up to 18 months
|
Baseline up to 18 months
|
Part A1.1: PK Plasma and Urine Concentration of M4076 Under Fed and Fasted Conditions
Time Frame: Day -1 up to Period 1 Day 1
|
Day -1 up to Period 1 Day 1
|
Part A2/A3: Time to Reach Maximum Plasma Concentration (tmax) of M1774
Time Frame: Day -4 up to Period 1 Day 1
|
Day -4 up to Period 1 Day 1
|
Part A2/A3: Duration of Response according to RECIST v1.1
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
Part A2/A3: Clinical benefit (either OR or stable disease for 6 months or more) according to RECIST v1.1.
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
Part A2/A3: Progression Free Survival according to RECIST v1.1 modified according to the Prostate Cancer Working Group 3 (PCWG-3), assessed by Investigator
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
Part A2/A3: Overall Survival
Time Frame: Up to 18 months after first dose administration
|
Up to 18 months after first dose administration
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS201924_0020
- 2022-500287-35-00 (Other Identifier: EU Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic or Locally Advanced Unresectable Solid Tumors
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Txinno Bioscience Inc.RecruitingLocally Advanced (Unresectable) or Metastatic Solid TumorsKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China
-
Astellas Pharma IncCompletedLocally Advanced (Unresectable) or Metastatic Solid Tumor MalignanciesJapan
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
PfizerTerminatedUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada
-
Vaccinex Inc.Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada